NYSE:BTX - New York Stock Exchange, Inc. - US1140821000 - Common Stock - Currency: USD
BlackRock Technology and Private Equity Term Trust
NYSE:BTX (2/21/2025, 8:04:35 PM)
After market: 7.64 -0.02 (-0.26%)7.66
-0.2 (-2.54%)
The current stock price of BTX is 7.66 USD. In the past month the price decreased by -34.41%. In the past year, price decreased by -97.76%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Brooklyn ImmunoTherapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. The company is headquartered in Brooklyn, New York and currently employs 10 full-time employees. The firm is focused on developing cytokine-based therapies for treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. Its lead product candidate, IRX-2, is a cytokine therapy, to treat patients with head and neck cancer. IRX-2 is a mixed, human-derived cytokine product with multiple active constituents including Interleukin-2 (IL2) and other key cytokines, which restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. The firm also has multiple cell and gene-editing therapies in preclinical development for various indications, including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. Its subsidiaries include Brooklyn ImmunoTherapeutics LLC, Novellus, Inc. and Novellus Therapeutics, Ltd.
BlackRock Technology and Private Equity Term Trust
140 58Th Street, Building A, Suite 2100
Brooklyn NEW YORK 92009 US
CEO: Allen Wolff
Employees: 10
Company Website: https://www.buzztime.com/
Phone: 12125821199.0
The current stock price of BTX is 7.66 USD. The price decreased by -2.54% in the last trading session.
The exchange symbol of BlackRock Technology and Private Equity Term Trust is BTX and it is listed on the New York Stock Exchange, Inc. exchange.
BTX stock is listed on the New York Stock Exchange, Inc. exchange.
5 analysts have analysed BTX and the average price target is 3.06 USD. This implies a price decrease of -60.05% is expected in the next year compared to the current price of 7.66. Check the BlackRock Technology and Private Equity Term Trust stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BlackRock Technology and Private Equity Term Trust (BTX) has a market capitalization of 450.60M USD. This makes BTX a Small Cap stock.
BlackRock Technology and Private Equity Term Trust (BTX) currently has 10 employees.
BlackRock Technology and Private Equity Term Trust (BTX) has a resistance level at 0.22. Check the full technical report for a detailed analysis of BTX support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BTX does not pay a dividend.
BlackRock Technology and Private Equity Term Trust (BTX) will report earnings on 2022-11-17, before the market open.
BlackRock Technology and Private Equity Term Trust (BTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.5).
ChartMill assigns a fundamental rating of 1 / 10 to BTX. Both the profitability and financial health of BTX have multiple concerns.
Over the last trailing twelve months BTX reported a non-GAAP Earnings per Share(EPS) of -0.5. The EPS decreased by -23.31% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -399.71% | ||
ROE | N/A | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 80% to BTX. The Buy consensus is the average rating of analysts ratings from 5 analysts.